| Autor: |
Lahiri, Durjoy, Seixas-Lima, Bruna, Roncero, Carlos, Verhoeff, Nicolaas Paul, Freedman, Morris, Al-Shamaa, Sarmad, Chertkow, Howard |
| Předmět: |
|
| Zdroj: |
Frontiers in Neurology; 2024, p01-10, 10p |
| Abstrakt: |
Introduction: With the advent of anti-ß-amyloid therapies, clinical distinction between Aß + and Aß- in cognitive impairment is becoming increasingly important for stratifying referral and better utilization of biomarker assays. Methods: Cognitive profile, rate of decline, neuropsychiatric inventory questionnaire (NPI-Q), and imaging characteristics were collected from 52 subjects with possible/probable AD. Results: Participants with Aß+ status had lower baseline MMSE scores (24.50 vs. 26.85, p = 0.009) and higher total NPI-Q scores (2.73 vs. 1.18, p < 0.001). NPI-Q score was found to be the only independent predictor for ß-amyloid positivity (p = 0.008). A simple scoring system, namely Clinical ß-Amyloid Positivity Prediction Score (CAPS), was developed by using the following parameters: NPI-Q, rapidity of cognitive decline, and white matter microangiopathy. Data from 48 participants were included in the analysis of accuracy of CAPS. CAP Score of 3 or 4 successfully classified Aß+ individuals in 86.7% cases. Discussion: Clinical ß-Amyloid Positivity Prediction Score is a simple clinical tool for use in primary care and memory clinic settings to predict ß-amyloid positivity in individuals with clinical Alzheimer Syndrome can potentially facilitate referral for Anti Aß therapies. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
